Fredun Pharmaceuticals Ltd. (FREDUN) 52 Week High Streak: Second Straight Session
- November 20, 2026
- Posted by: Kunal Singla
- Category: News
Fredun Pharmaceuticals Ltd. has now set a fresh 52-week high for its second straight session, with the stock moving up 5.14% across the streak and touching Rs 1,730.8 in the latest move. The latest Univest figures confirm the repeated-high pattern, but they do not establish a company-specific catalyst for the continued rise.
At 20 November 2026 at 9:22 AM IST, Fredun Pharmaceuticals Ltd. traded at Rs 1,718.3 versus the previous close of Rs 1,707.7. It opened at Rs 1,712 and moved between Rs 1,704.95 and Rs 1,730.8, with a market capitalisation of Rs 2,798.83 crore. For readers, a repeated 52 Week High Streak is more than a one-off breakout: it shows that the stock has printed fresh yearly highs on back-to-back sessions, while the current pattern remains a price fact rather than a confirmed business trigger.
Fredun Pharmaceuticals Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,718.3 |
| Previous Close | Rs 1,707.7 |
| Today's Move | +Rs 10.6 (+0.62%) |
| Open | Rs 1,712 |
| High | Rs 1,730.8 |
| Low | Rs 1,704.95 |
| Market Capitalisation | Rs 2,798.83 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,718.3 versus the previous close of Rs 1,707.7, a rise of 0.62%. The stock opened at Rs 1,712, reached a high of Rs 1,730.8 and touched a low of Rs 1,704.95.
Fredun Pharmaceuticals Ltd. 52 Week High Streak starts with the intraday picture, because today’s price action gives the immediate context for the second straight yearly high. The stock was last traded at Rs 1,718.3, up Rs 10.6 or 0.62% from the previous close of Rs 1,707.7. It opened at Rs 1,712, moved to a high of Rs 1,730.8 and a low of Rs 1,704.95, and the latest price stood near the upper end of that range as it touched the fresh peak. Market capitalisation stood at Rs 2,798.83 crore.
For a Fredun Pharmaceuticals Ltd. 52 Week High Streak article, this is the core day-to-day read: the stock is not just above the previous close, it is also extending the one-year high sequence that began on the prior trading date. The current print is only one part of the picture, but it supports the broader pattern that the market has now marked a higher reference point on two consecutive sessions. That is the difference between a one-day breakout and a Fredun Pharmaceuticals Ltd. 52 Week High Streak.
What the Repeated 52-Week Highs Show
Fredun Pharmaceuticals Ltd. 52 Week High Streak matters because the stock has now set a fresh one-year high on both sessions in the current run, not just on one isolated day. The cumulative move across the streak is 5.14%, and the latest high of Rs 1,730.8 is also the current 52-week peak. The key point is simple: the repeated-high pattern is confirmed, while the reason behind it is not established by the price data alone.
In a Fredun Pharmaceuticals Ltd. 52 Week High Streak, the most useful comparison is not just with the previous close, but with the earlier high reference. The stock has moved from the prior session’s breakout level into a new higher peak, which means the one-year range has been reset twice in quick succession. That tells readers that the market has priced the stock at a new high twice, but it does not tell them why. The numerical record supports the pattern; it does not confirm a catalyst.
For investors tracking a Fredun Pharmaceuticals Ltd. 52 Week High Streak, the right question is whether the company’s earnings base and valuation base can support the newer price zone. Since the share price has moved higher while the business metrics below remain the same, the change in the multiples comes from price alone, not from any fresh revision in reported operating figures.
Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,798.83 crore |
| P/E Ratio | 55.22x |
| P/B Ratio | 8.44x |
| ROE | 16.09% |
| ROCE | 21.34% |
| EPS | Rs 30.93 |
| Book Value Per Share | Rs 202.35 |
| Dividend Yield | 0.01% |
Fredun Pharmaceuticals Ltd. (FREDUN) fundamental metrics show P/E 55.22x, P/B 8.44x, ROE 16.09%, ROCE 21.34%. These figures provide context only and are not a buy or sell signal.
Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 2,798.83 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 55.22x, P/B at 8.44x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.09% and ROCE of 21.34%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 30.93, book value per share of Rs 202.35, dividend yield of 0.01%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.75x, median ROE of 11.22%, median ROCE of 13.1%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 55.22x |
| Benchmark Median P/E | 30.75x |
| Benchmark Average P/E | 59.39x |
| Benchmark P/E Range | 2.73x to 1,399.41x |
| Company P/B Ratio | 8.44x |
| Benchmark Median P/B | 2.84x |
| Company ROE | 16.09% |
| Benchmark Median ROE | 11.22% |
| Company ROCE | 21.34% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 2,798.83 crore |
| Benchmark Median Market Cap | Rs 766.63 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 55.22x, which is above the benchmark median of 30.75x, a difference of +79.58%. On its own, the P/E gap is a valuation reference point, not a trading call.
Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 16.09%, which is above the benchmark median of 11.22%, a difference of +43.4%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 21.34%, which is above the benchmark median of 13.1%, a difference of +62.9%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,968.06 | 34.92 | 1.94 | 3.47 | 4 |
| Advanced Enzyme Technologies Ltd. | ADVENZYMES | 3,079.88 | 19 | 2.04 | 11.43 | 15.27 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 3,139.96 | 83.52 | 2.15 | -0.63 | 4.61 |
| Unichem Laboratories Ltd. | UNICHEMLAB | 3,400.95 | 9.97 | 1.22 | 9.81 | 10.68 |
| Sakar Healthcare Ltd. | SAKAR | 2,246.57 | 50.67 | 6.28 | 10.04 | 12.52 |
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 55.22x compared with the displayed peer median of 34.92x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 16.09% compares with a peer median of 9.81% across the companies shown in the table. ROCE stood at 21.34% versus the displayed peer median of 10.68%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 2,798.83 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching Fredun Pharmaceuticals Ltd.
- Fredun Pharmaceuticals Ltd. 52 Week High Streak has lasted two straight sessions, with a fresh yearly peak on each day.
- The cumulative move across the streak is 5.14%, which is the key multi-session number to track.
- The latest 52-week high is Rs 1,730.8, and that is the current high-water mark for the stock.
- The company’s ROE of 16.09% and ROCE of 21.34% remain above the industry medians in the snapshot.
- The stock trades at 55.22 times earnings and 8.44 times book, which keeps valuation in focus after the streak.
About Fredun Pharmaceuticals Ltd.
Fredun Pharmaceuticals Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. For a Fredun Pharmaceuticals Ltd. 52 Week High Streak, the business context that matters most is its position as a mid-sized listed company with a market capitalisation of Rs 2,798.83 crore and return ratios above the same-industry median. That helps frame the streak without turning it into a broader company story.
The company’s recent price record also matters because the stock is now at a new yearly high for the second straight session. Readers tracking Fredun Pharmaceuticals Ltd. 52 Week High Streak should therefore keep the business profile in view alongside the valuation multiple, return ratios and sector comparison rather than reading the move in isolation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What is Fredun Pharmaceuticals Ltd. 52 Week High Streak?
Ans. Fredun Pharmaceuticals Ltd. 52 Week High Streak means the stock has set a fresh 52-week high on consecutive trading sessions. In this case, the streak has reached a second straight session, with the latest peak at Rs 1,730.8.
For how many sessions has Fredun Pharmaceuticals Ltd. set a fresh 52-week high?
Ans. Fredun Pharmaceuticals Ltd. has set a fresh 52-week high for two consecutive sessions.
By how much has Fredun Pharmaceuticals Ltd. moved across the streak?
Ans. The cumulative move across the Fredun Pharmaceuticals Ltd. 52 Week High Streak is 5.14%. That figure captures the full streak movement, not just the latest intraday change.
What is the latest 52-week high for Fredun Pharmaceuticals Ltd.?
Ans. The latest 52-week high is Rs 1,730.8. The stock also touched that level during the current session, making it the fresh peak for the second straight trading day.
How did Fredun Pharmaceuticals Ltd. trade relative to the previous close?
Ans. The stock last traded at Rs 1,718.3 versus the previous close of Rs 1,707.7. That is a gain of Rs 10.6, or 0.62%, from the prior session’s settled level.
Is there a confirmed company-specific catalyst for the repeated highs?
Ans. No confirmed company-specific catalyst is established by the price data alone. The numbers confirm a repeated-high pattern, but they do not explain why the stock is continuing to print new yearly highs.
How is Fredun Pharmaceuticals Ltd. valued after the streak?
Ans. Fredun Pharmaceuticals Ltd. trades at a P/E of 55.22 and a P/B of 8.44. Those multiples are higher than the same-industry medians in the snapshot, so the streak has left valuation in a richer zone.
How does the stock compare with its industry medians?
Ans. The stock’s P/E, P/B, ROE and ROCE can be compared with the same-industry medians. Fredun Pharmaceuticals Ltd. stands above the median on return ratios, but it also trades above the median on valuation.
Track Fredun Pharmaceuticals Ltd. Share Price on Univest
Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Follow Fredun Pharmaceuticals Ltd. 52 Week High Streak alongside live price updates, valuation metrics and sector comparison on Univest. The stock page brings the latest share price, market capitalisation and key ratios into one place, which makes it easier to monitor how the repeated yearly highs evolve from here.